证券代码：600196 股票简称：复星医药 编号：临 2024-169 上海复星医药（集团）股份有限公司 关于控股子公司获药品注册批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司重庆药 友制药有限责任公司的注射用盐酸罗沙替丁醋酸酯（以下简称"该新药"）的上市注 册申请于近日获国家药品监督管理局批准。 二、该新药的基本情况 药品通用名称：注射用盐酸罗沙替丁醋酸酯 规格：75mg 注册分类：化学药品 3 类 上市许可持有人/药品生产企业：重庆药友制药有限责任公司 药品批准文号：国药准字 H20249114 剂型：注射剂 四、对上市公司的影响及风险提示 该新药本次获批上市，可为上消化道出血患者用药提供更多的选择，并丰富本 集团产品线。预计该新药本次获批上市不会对本集团现阶段业绩产生重大影响。 由于医药产品的行业特点，药品上市后的具体销售情况可能受到（包括但不限 于）用药需求、市场竞争、销售渠道等因素影响，具有较大的不确定性。敬请广大 投资者注意投资 ...

证券代码：600196 股票简称：复星医药 编号：临 2024-168 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ●本次担保： 1、本公司拟为控股子公司复星健康向上海农商行申请的人民币 5,000 万元 的流动资金贷款提供连带责任保证担保； 2、本公司拟为控股子公司复星医药产业向光大银行申请的不超过人民币 16,000 万元的专项并购贷款提供连带责任保证担保。 ●是否有反担保： 由于复星健康股东之一的宁波砺定系复星健康股权激励计划的持股平台，其 股东宁波砺星、宁波砺坤（均为员工参与激励计划的间接持股平台）已分别质押 各自持有的宁波砺定 8.9969%、3.4878%的合伙份额为前述第 1 项担保提供反担 保。 ●实际为被担保方提供的担保金额： 截至 2024 年 10 月 30 日，包括本次担保在内，本集团实际为复星健康担保 金额折合人民币约 174,939 万元、为复星医药产业担保金额折合人民币约 935,635 万元。 ...

复星医药：控股子公司获药品注册批准 财联社10月30日电，复星医药公告称，其控股子公司重庆药友 制药有限责任公司的注射用盐酸罗沙替丁醋酸酯的上市注册申请近日获国家药品监督管理局批准。 该新药主要用于上消化道出血患者治疗，预计不会对公司现阶段业绩产生重大影响。 查看公告原文 ...

Investment Rating - The report assigns a "Buy" rating for both A and H shares of the company, indicating a potential upside of 15% to 35% [6][8]. Core Insights - The company reported a revenue of 30.91 billion RMB for the first three quarters of 2024, with a year-over-year growth of 0.7%. The net profit attributable to the parent company was 2.01 billion RMB, down 11.9% year-over-year, but the non-recurring net profit was 1.84 billion RMB, showing a growth of 24.6% year-over-year [6]. - Excluding COVID-related products, the company's revenue for the first three quarters of 2024 grew approximately 5.7%, driven by steady growth in innovative drugs [6][7]. - The company experienced a significant increase in net profit for Q3 2024, with a year-over-year growth of 55.4%, attributed to various factors including a lower base from the previous year and improved product mix [7]. Company Overview - The company operates primarily in the pharmaceutical and biotechnology industry, with a product mix that includes 61.4% from drug manufacturing and R&D, 15.1% from medical devices and services, and 13.4% from pharmaceutical distribution and retail [3]. - The major shareholder is Shanghai Fosun High Technology Group Co., Ltd., holding 33.30% of the shares [2]. Financial Performance - The company’s A-share price as of October 29, 2024, was 26.04 RMB, with a market capitalization of 55.165 billion RMB [2]. - The projected net profits for 2024, 2025, and 2026 are 2.9 billion RMB, 3.5 billion RMB, and 4.1 billion RMB, respectively, with year-over-year growth rates of 20.2%, 22.5%, and 17.3% [8][9]. - The earnings per share (EPS) for the same years are projected to be 1.1 RMB, 1.3 RMB, and 1.5 RMB, with corresponding price-to-earnings (P/E) ratios for A shares of 24X, 20X, and 17X [8][9]. Market Position - The company’s stock has shown a price increase of 13.8% over the past month, 11.7% over the past three months, but a decline of 3.3% over the past year [2]. - The company is actively optimizing its R&D pipeline and financial structure, which is expected to enhance future growth prospects [8].

登記股東之名稱及地址 上海復星醫藥（集團）股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） (股份代號: 02196) 上海復星醫藥（集團）股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 1. 可供採取行動的公司通訊 4 本公司將以電子通訊方式（通過電子郵件）向股東個別地發送可供採取行動的公司通訊。如果本公司沒有獲 取股東的電子郵箱地址或其提供的電子郵箱地址無效 5，本公司將以印刷本形式向股東發送可供採取行動的 公司通訊，連同一份索取股東有效電子郵箱地址的表格，以便將來以電子通訊方式發送可供採取行動的公司 通訊。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 2024 年 10 月 29 日 尊敬的股東 發佈公司通訊之新安排 簡介 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）新規則第 2.07A 條 1 以及上海復星 醫藥（集團）股份有限公司（「本公司」）的公司章程，本公司將以電子通訊方式向其股 ...

（於中華人民共和國註冊成立的股份有限公司） （Stock Code 股份代號：2196） 29 October 2024 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上海復星醫藥（集團）股份有限公司 (a joint stock limited company incorporated in the People's Republic of China with limited liability) 以電子方式發布公司通訊之安排 根據已於2023年12月31日生效的經修訂香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」），上海復星醫藥（集團）股份有限公司（「本公司」） 採納透過電子方式向其非登記股東發佈日後所有公司通訊（「公司通訊」）的新安排。日後所有公司通訊的中、英文版本將在本公司網站www.fosunpharma.com和聯交 所網站www.hkexnews.hk（「網站版本」）上提供，以代替印刷本。除非 閣下提出要求，公司不會再向 閣下郵寄公司通訊的印刷本。 Dear Non-registered holder of H shares, ...

Financial Performance - The company's operating revenue for Q3 2024 reached RMB 10,449,076,271.75, representing a year-on-year increase of 12.30%[4] - Net profit attributable to shareholders for the same period was RMB 785,843,766.10, showing a significant increase of 55.43% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 582,174,869.86, reflecting a substantial increase of 474.77% compared to the previous year[4] - The net cash flow from operating activities for Q3 2024 was RMB 1,079,633,457.17, an increase of 65.68% year-on-year[4] - Basic earnings per share for the quarter were RMB 0.29, up 52.63% from the same period last year[4] - Diluted earnings per share also stood at RMB 0.29, marking a 52.63% increase year-on-year[4] Assets and Liabilities - Total assets at the end of the reporting period were RMB 115,264,761,757.14, a year-on-year increase of 1.58%[5] - Equity attributable to shareholders at the end of the reporting period was RMB 47,301,473,095.24, reflecting a growth of 3.54% compared to the previous year[5] - Current assets totaled RMB 34.53 billion, up from RMB 33.79 billion, indicating a growth of about 2.18%[27] - Short-term borrowings increased to RMB 18.68 billion from RMB 14.73 billion, representing a rise of approximately 26.67%[28] - Total liabilities decreased slightly to RMB 56.07 billion from RMB 56.85 billion, a decline of about 1.37%[28] - The total owner's equity rose to RMB 59.19 billion from RMB 56.62 billion, an increase of approximately 4.53%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 262,536[10] - Shanghai Fosun High Technology (Group) Co., Ltd. holds 889,890,955 shares, accounting for 33.30% of the total shares[10] - HKSCC Nominees Limited holds 551,372,815 shares, representing 20.63% of the total shares[10] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding over 889 million shares[11] - The company has a diverse shareholder base, including domestic and foreign institutional investors[10] - The report indicates that there are no shares under pledge or frozen status for the major shareholders[10] Research and Development - Research and development investment totaled RMB 3.915 billion in the first three quarters of 2024, with RMB 2.648 billion allocated specifically for R&D expenses[14] - The company is focusing on innovative drugs and high-value medical devices, continuously promoting lean operations and cost reduction[13] - The company is implementing an open R&D model, including the establishment and management of industrial funds to support the incubation and investment of R&D projects[14] - The company has prioritized key projects in its R&D management to ensure efficient results transformation and continuous launch of innovative products[14] Clinical Trials and Approvals - The company received IND approval for the injectable A-type botulinum toxin (brand name: Daxif) for the treatment of moderate to severe glabellar lines in China[17] - The company’s innovative anti-HER2 monoclonal antibody HLX22 showed significant improvement in first-line treatment for HER2-positive advanced or metastatic gastric/gastroesophageal junction cancer in a Phase II clinical trial[17] - The company’s HLX11 (recombinant anti-HER2 monoclonal antibody) entered Phase II clinical trials for the treatment of HER2-positive and HR-negative early or locally advanced breast cancer[15] - The company’s SBK 010 oral solution received IND approval for the treatment of mild to moderate acute ischemic stroke[15] - The company’s 23-valent pneumococcal polysaccharide vaccine received approval for Phase I and III clinical trials for the prevention of pneumococcal diseases in China[16] - The company’s freeze-dried human rabies vaccine received IND approval for Phase I and III clinical trials for rabies prevention[16] Financial Activities - Fosun Pharma increased its stake in Kite Pharma to 100%, acquiring an additional 50% equity, which will be consolidated into the group's financial statements[19] - The company completed an A-share repurchase plan, buying back 5,677,700 shares, approximately 0.21% of total shares, for a total amount of about RMB 126.64 million[20] - The H-share repurchase plan saw the company buy back 5,471,500 shares, about 0.20% of total shares, with a total expenditure of approximately HKD 66.9 million[21] - The controlling shareholder, Fosun High Technology, increased its holdings by 4,295,000 A-shares, representing 0.16% of total shares, with a total investment of approximately RMB 101.19 million[22] Comprehensive Income - The company reported a total comprehensive income of RMB 2.30 billion for the first three quarters of 2024, down from RMB 3.04 billion in 2023, a decline of about 24.1%[30] - The comprehensive income total for the first three quarters of 2024 was CNY 1.24 billion, compared to CNY 943.78 million in the same period of 2023, reflecting an increase of approximately 31.5%[36] Cash Flow - The company reported a decrease in other comprehensive income to RMB -1.47 billion from RMB -1.30 billion, reflecting a decline of approximately 12.69%[28] - The total cash inflow from investment activities was RMB 1,823,762,368.12, down 41.8% from RMB 3,127,265,876.22 in the first three quarters of 2023[32] - The net cash flow from financing activities was negative RMB 502,289,412.69, compared to a negative RMB 396,579,604.48 in the same period of 2023[32] - The company received RMB 21,739,468,572.59 in loans during the first three quarters of 2024, compared to RMB 18,051,361,530.05 in the same period of 2023, marking an increase of 20.5%[32]

复星医药：前三季度净利润20.11亿元 同比下降11.93% 财联社10月29日电，复星医药发布2024年第三季 度报告，前三季度实现营业收入309.12亿元，同比增长0.69%；净利润20.11亿元，同比下降11.93%。 其中，第三季度实现营业收入104.49亿元，同比增长12.3%；净利润7.86亿元，同比增长55.43%。 查看公告原文 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 召開2024 年第三季度業績說明會的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 中國，上海 2024 年1 0 月2 9 日 於本公告日期，本公司之執行董事為吳以芳先生、王可心先生、關曉暉女士及文德鏞先生；本公司之非執 行董事為陳 啟 宇先生、徐曉亮先生、潘東輝先生及陳玉卿先生；以及本公司之獨立非執行董事為李玲女士、 湯谷良先生、王全弟先生及余梓山先生。 * 僅供識別 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 证券 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司股權激勵計劃實施進展暨關聯交易的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 吳以芳 证券代码：600196 股票简称：复星医药 编号：临 2024-166 上海复星医药（集团）股份有限公司 关于控股子公司股权激励计划实施进展 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...